2026-04-29T10:17:36-07:00 2025-12-31 990 2025-01-01 270924627 DRAVET SYNDROME FOUNDATION INC DRAV 2033921955 PO Box 3026 Cherry Hill NJ 08034 Ross Nicholas Board Chair 2033921955 2026-04-27 2025 2025-03-06 01:10:19Z Mary Anne Meskis PO Box 3026 Cherry Hill NJ 08002 5169419 0 X www.dravetfoundation.org X 2009 CT The mission of the Dravet Syndrome Foundation is to aggressively raise funds for Dravet syndrome & related epilepsies; support & fund research; increase awareness; & provide support to affected individuals & families. 8 8 13 100 0 0 3106931 3831992 734789 600050 304376 273034 75526 47167 4221622 4752243 2509120 3290753 0 0 841275 909231 0 0 231048 908777 583681 4259172 4783665 -37550 -31422 8536916 9833611 1510060 2652358 7026856 7181253 The mission of the Dravet Syndrome Foundation is to aggressively raise funds for Dravet syndrome & related epilepsies; support & fund research; increase awareness; & provide support to affected individuals & families. We understand the ongoing need to fund innovative research, the urgency in finding better treatments, the motivation of our donors to make an impact specifically in the fields of Dravet syndrome and related epilepsies, the importance of transparency and accountability of not only our organization, but the researchers that we fund, and the need for global collaboration in order to find a cure. 0 0 3444887 3262635 0 DSF funds research for better treatments and a cure for Dravet syndrome and related epilepsies by awarding research grants to qualified scientists and clinicians. These grants fund initial research hypotheses that have not been fully explored. The results extracted from this type of research will help bring untested research to the point that it can qualify for larger governmental funding. Since 2009, DSF has awarded over $14.1 million to 84 research endeavors. Research areas include SUDEP, gene therapy, drug discovery, screening, treatments, genetics, epidemiology and neuronal networks. DSF has also supported the development of a commercial line of iPSC cells for researchers and the biotechnology industry. DSF's Chief Scientific Officer serves as the liaison between the medical/scientific community and DSF, developing strategies to support research, manage DSF's involvement in projects, and move projects forward with assistance in project management, manuscript preparation, and other writing opportunities. The Chief Scientific Director acts as a representative of DSF to other institutions including NIH, FDA, pharma and biotechnology companies. 459959 28118 414125 Receiving a diagnosis of Dravet syndrome (DS) can be overwhelming, leaving families with many unanswered questions. To support our patient community, DSF provides a variety of educational, advocacy, and support resources: These initiatives are part of DSF's commitment to providing vital resources and fostering a strong, supportive community for those affected by Dravet syndrome. DSF Family Network: Open to any parent, legal guardian, or sibling interested in our advocacy services and programs, the Family Network keeps members informed about new advocacy tools, clinical trials, educational opportunities, and fundraising events. It also includes moderated private Facebook support groups for parents and caregivers of individuals with Dravet syndrome. Membership is limited to those legally responsible for making medical decisions for the patient. In 2025, 280 people joined the Family Network. Newly Diagnosed Kits: DSF provides newly diagnosed families with a kit that includes a guidebook for navigating life after diagnosis, a medication bag, and other materials to ensure they have the knowledge and tools needed for their child's care. In 2025, DSF distributed 115 kits. Patient Assistance Grants: The DSF Patient Assistance Grant Program offers financial support to patients with Dravet syndrome and related SCN1A epilepsies for medical equipment, therapy devices, and educational aids not covered by private insurance or other programs. This program is available to all patients worldwide who are members of the DSF Family Network. Since 2009, DSF has awarded $306,000 to 265 families. Birthday Buddies: Families can register their loved one with Dravet syndrome to receive a birthday card and small gift from DSF's mascot, Aurora, around their birthday. In 2025, DSF sent 677 gifts. Super Siblings Club: DSF provides a day camp at our biennial conference and annual Day of Dravet workshops for siblings of individuals with Dravet syndrome. These events offer a fun and supportive environment for siblings to connect, express their feelings, and bond with others facing similar challenges. Bereavement Support: Losing a loved one, especially a child, is profoundly painful. DSF offers resources for coping with grief, including a Bereavement Support Group and Remembrance Wall. Legislative Advocacy Program: We are committed to keeping our patient community informed about legislative actions affecting Medicaid and rare disease research, which are essential for maintaining access to care and driving advancements in treatment for Dravet syndrome. By ensuring our constituents have accurate and nonpartisan information, they can advocate for their loved one and family effectively. Biennial Conference: This 3-day event brings together families, caregivers, clinicians, researchers, and pharmaceutical professionals to collaborate on improving the lives of those with Dravet syndrome. The conference features presentations on the latest research and patient care, fostering new relationships and collaborations. Over 500 people attended the 2024 conference. Day of Dravet Workshops: Held in alternating years from the biennial conference, these workshops offer families the opportunity to learn about research, treatment options, and connect with others. Sessions are led by community experts, including fellow parents. The workshops also include our VIP Sib Camp and activities for patients. In 2025, 470 attendees, representing 123 families participated at workshops in Texas (San Antonio), Tennessee (Sevierville), Washington (Tacoma), Illinois (Gurnee), and Pennsylvania (Hershey). 168401 0 185925 DSF produces an annual research roundtable meeting to provide opportunity for researchers and clinicians to collaborate and discuss better treatment options and a roadmap toward a cure and how to best facilitate both. This meeting started in 2010 as a brainstorming session for the few researchers working on Dravet syndrome. DSF hosted its 16th annual Research Roundtable with nearly 190 participants. 0 0 0 4073247 1 1 0 1 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 14 0 1 13 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 8 8 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA IL KS KY MA MD MI MN MO MS NC NH NJ NM NY OR PA RI SC TN VA WI WV X X X Jamie Cohen 2033921955 522 Mackin Drive Cherry Hill NJ 08002 Mary Anne Meskis Chief Executive Officer 40 0 X 179356 0 7165 Veronica Hood PhD Chief Scientific Officer 40 0 X 174406 0 6967 Jamie Cohen CPA Chief Financial Officer 40 0 X 114984 0 4590 Ross Nicholas Chair 1 0 X X 0 0 0 Gail Farfel PhD Vice Chair 1 0 X X 0 0 0 Claire Carey Secretary 1 0 X X 0 0 0 Josh Goldman Treasurer 1 0 X X 0 0 0 Nathan Batt Director 1 0 X X 0 0 0 Bill Kirshner MD Director 1 0 X 0 0 0 Amanda Prather PA-C Director 1 0 X 0 0 0 Mike Chieco Director 1 0 X 0 0 0 Ted Odlaug PhD Director 1 0 X X 0 0 0 Joseph Sullivan MD Director 1 0 X 0 0 0 468746 0 18722 3 0 1 0 Geben Communication 143 E Main St 200 Columbus OH 43215 Media Relations 150000 1 0 0 1977729 0 0 1854263 0 3831992 Professional Education & Meetings 813319 185925 185925 0 0 Patient & Family Services 813319 414125 414125 0 0 0 0 0 0 600050 273034 0 0 273034 0 0 0 0 0 0 0 0 0 0 0 0 464343 1977729 417176 47167 0 47167 0 4752243 600050 0 320201 2777635 2777635 25786 25786 487332 487332 499858 223055 270399 6404 325844 138112 37312 150420 10820 5544 133 5143 6889 3600 566 2723 65820 28580 24096 13144 11500 11500 156594 120400 36194 184 184 65777 18280 26376 21121 32847 6699 23465 2683 4284 1428 1428 1428 60237 44990 10462 4785 196170 187064 5388 3718 2951 2951 6093 777 4905 411 Charity Registration Fees 4446 0 4446 0 Dues & Subscriptions 42598 3965 19565 19068 4783665 4073247 479370 231048 383617 420091 1696246 1545160 36352 175474 19025 45214 56059 129081 11435 2951 8484 6345617 7510107 8536916 9833611 50233 110097 1442946 2520965 16881 21296 0 0 1510060 2652358 X 6988189 6761560 38667 419693 7026856 7181253 8536916 9833611 X -31422 143239 0 0 0 42580 X 0 1 X 1 0 X 1437446 1713227 2530132 3106930 3831992 12619727 1437446 1713227 2530132 3106930 3831992 12619727 12619727 5151 88364 218415 304376 273034 889340 13509067 0.93417 0.94060 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1682 2099 3781 4779885 4783666 389183 97296 0 0 0 0 362959 389183 752142 1128213 0 0 9282 3781 13063 0 0 90740 97296 188036 282054 0 0 2984 1682 4666 937673 360009 170628 0 0 0 1468310 549579 271071 117023 0 0 0 937673 228680 250000 70899 0 0 0 549579 275171 0 -46491 0 0 0 228680 101887 150000 23285 0 0 0 275172 0.9993 0.0007 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 11435 2951 8484 0 0 0 0 8484 0 0 X 4895482 143239 0 0 0 143239 4752243 0 0 0 4752243 4741085 0 0 0 0 0 4741085 0 42580 42580 4783665 Schedule D, Part V, Line 4 The purpose of the Endowment is to support the mission of the Foundation by providing an alternative source of funds for current and future use. The endowment has two primary goals. First, the principal of the endowment's assets which are not self-funded, must be preserved in perpetuity; second, the endowment should strive to achieve investment returns sufficient to supplement ongoing Foundation operations. To the extent these first two goals are achieved, the Foundation endeavors to grow the endowment so that it represents an even larger source of funding for future generations. Schedule D, Part X, Line 2 DSF recognizes the effect of tax positions only when they are more than likely than not of being sustained. Management has determined that DSF had no uncertain tax positions that qualify for either recognition or disclosure in the financial statements. In the normal course of business DSF's tax filings are subjected to examination by federal and state authorities. The tax returns for the years ended December 31, 2022 and forward are subject to examination by taxing authorities. Schedule D, Part XII, Line 4b Present value discount on grant payable not recognized on Form 990. 1 Europe (including Iceland and Greenland) 0 0 Grantmaking 355000 Middle East and North Africa 0 0 Grantmaking 130000 North America (including Canada and Mexico, but not the United States) 0 0 Grantmaking 2332 0 0 487332 Europe (including Iceland and Greenland) 1. Leiden University Medical Center - Research Grant: Neurophysiological Characterization of the Therapeutic Effect of Exogenous Nav1.1 Channels - $110,000. 2.Royal College of Surgeons Ireland - Postdoctoral Fellowship: Multi-Target Strategy for Dravet Syndrome: Enhancing Sodium Channels and GABA Receptors via miRNA Inhibition - $75,000. 3. Institut de Génétique Moléculaire de Montpellier, in conjunction with Tel Aviv University and The Children's Hospital of Philadelphia - Transformational Science Grant: Molecular Characterization of the Therapeutic Effect of Exogenous Nav1.1 - $170,000. Details for each of these projects can be found at https://dravetfoundation.org/dsf-funded-research/ 355000 Wire Transfer 0 FMV Middle East and North Africa Tel Aviv University in conjunction with Institut de Génétique Moléculaire de Montpellier and The Children's Hospital of Philadelphia - Transformational Science Grant: Molecular Characterization of the Therapeutic Effect of Exogenous Nav1.1. This study investigates how introducing functional Nav1.1 sodium channels affects cellular and molecular processes. The goal is to better understand how restoring this protein alters neuronal signaling, protein interactions, and downstream pathways. By mapping these effects, researchers aim to identify mechanisms of therapeutic benefit and potential biomarkers of response. Insights from this work will guide optimization of Nav1.1-based therapies and support the development of more targeted and effective treatment strategies. 130000 Wire Transfer 0 FMV 3 0 0 0 0 0 0 0 Schedule F, Part I, Line 2 DSF provides funds for research. The organizations receiving this assistance are required to provide written progress reports on their research into finding a cure for Dravet syndrome and related epilepsies. The Chief Scientific Officer of DSF reviews the written progress reports and discusses the research projects and progress with the awarded organization. DSF also provides funding to patients with Dravet syndrome and related epilepsies for necessary medical equipment, therapy devices and education aids associated with these conditions that are not covered through private insurance or other assistance programs. Applicants are required to submit an application that includes a recent letter from the child's healthcare provider explaining the medical necessity of the request and when possible, a letter of denial from the insurance provider. Dance for Dravet 889679 699303 190376 0 0 14297 77846 7262 30866 City Bash: Rally for Dravet 489973 437161 52812 0 0 30310 26844 1925 30309 19 1062420 841264 221156 0 0 29242 73519 17325 77430 2442072 1977728 464344 0 0 73849 178209 26512 138605 417175 47169 1 Regents of the University of Michigan 3003 South State Street Ann Arbor MI 48109 386006309 501(c)(3) 779250 0 FMV 1. University of Michigan - Special Project Funding:Understanding Phenotypes and Biomarkers Leading to SUDEP in a Transgenic Rabbit Model - $750,000. This study uses a transgenic rabbit model of Dravet syndrome to identify observable traits and measurable biomarkers associated with increased risk of sudden unexpected death in epilepsy (SUDEP). The goal is to characterize physiological, behavioral, and cardiac indicators that precede critical events. By establishing reliable biomarkers, the research aims to improve risk stratification and enable earlier intervention. The model also provides a platform for testing preventative strategies and understanding underlying mechanisms. 2. In conjunction with Stanford University - Special Project Funding: Identification of Behavioral Biomarkers in Children with DS: A Pilot Study - $29,250. Details for each of these projects can be found at https://dravetfoundation.org/dsf-funded-research/ Regents of the University of Colorado 1800 N Grant St Ste 200 Denver CO 80203 846000555 501(c)(3) 662231 0 FMV Dravet Syndrome Natural History Study. The Natural History study will recruit and follow children and adults with Dravet Syndrome to track how often and how severely issues like behavior, development, sleep, appetite, autonomic symptoms, and motor function occur and change over time. The study will establish a robust database that will capture standardized clinical, neuropsychological, and parent-reported data on key signs and symptoms across the lifetime. The study will also explore how these outcomes connect to specific genetic changes to better understand how different types of mutations might influence Dravet Syndrome. This study will increase understanding of Dravet syndrome, and lead to better design of treatments and clinical trials. Allen Institute 615 Westlake Ave N Seattle WA 98109 912155317 501(c)(3) 449785 0 FMV Circuit-Selective Whole SCN1A Gene Delivery for Dravet Syndrome. This research focuses on delivering a full-length functional gene specifically to affected neural circuits rather than broadly across the brain utilizing different mouse models of Dravet syndrome. The goal is to improve therapeutic precision while minimizing off-target effects. Using advanced vector systems and targeting strategies, the team aims to restore gene function in key cell populations responsible for disease symptoms. This approach seeks to enhance efficacy and safety of gene therapy by tailoring delivery to the most relevant neural networks. The Board of Trustees of the Leland Stanford Junior University 450 Jane Stanford Way Stanford CA 943052004 941156365 501(c)(3) 309500 0 FMV Identification of Behavioral Biomarkers in Children with DS: A Pilot Study In conjunction with University of Michigan, this pilot study seeks utilize AI and machine learning to identify subtle but measurable behavioral patterns that can serve as biomarkers for disease progression and treatment response in Dravet syndrome that would be undetectable using traditional observational methods. Researchers aim to define objective indicators of cognitive, social, and functional changes with the goal to improve clinical trial endpoints and enable more sensitive tracking of outcomes. Findings may support the development of better tools for evaluating therapeutic impact in patient populations. Children's Hospital of Pennsylvania 2716 South Street Philadelphia PA 191462305 231352166 501(c)(3) 240000 0 FMV 1. In conjunction with Tel Aviv University and Institut de Génétique Moléculaire de Montpellier - Transformational Science Grant: Molecular Characterization of the Therapeutic Effect of Exogenous Nav1.1 - $150,000. 2. In conjunction with MIT and Harvard University - Research Grant: Base Editing for the Treatment and Prevention of Dravet Syndrome - $90,000. Details for each of these projects can be found at https://dravetfoundation.org/dsf-funded-research/ The Broad Institute of MIT and Harvard 415 Main Street Cambridge MA 02142 263428781 501(c)(3) 100000 0 FMV In conjunction with The Children's Hospital of Philadelphia, Base Editing for the Treatment and Prevention of Dravet Syndrome. This project aims to develop a precision gene-editing approach using base editing technology to directly correct disease-causing mutations at the DNA level using a mouse model of Dravet syndrome. The goal is to create a durable, potentially one-time treatment that can restore normal gene function without introducing double-strand DNA breaks. Researchers are working to optimize delivery systems, improve editing efficiency, and evaluate safety in relevant models. Ultimately, the project seeks to establish a foundation for preventive or early-intervention therapies that address the root genetic cause rather than managing symptoms. The Research Foundation for the State University of New York 35 State Street Albany NY 12207 141368361 501(c)(3) 100000 0 FMV Award Supplement for Genetic Substrates and Physiological Triggers for Autonomic and Cardiac Abnormalities. This project investigates the genetic and physiological factors underlying autonomic and cardiac dysfunction in Dravet syndrome and closely related epilepsy disorders. The goal is to identify specific triggers and biological mechanisms that contribute to irregular heart rhythms and autonomic instability. Researchers are integrating genetic analysis with physiological monitoring to better understand risk factors. Insights from this work may inform strategies to predict, monitor, and reduce life-threatening complications for Dravet syndrome. The Children's Hospital Corporation dba Boston Children's Hospital 300 Longwood Avenue Boston MA 02115 042774441 501(c)(3) 77500 0 FMV Selective Activation of Hippocampal Parvalbumin Interneurons via Focused Ultrasound Neuromodulation for Seizure Suppression in SCN1A Mice. This project evaluates a non-invasive neuromodulation approach using focused ultrasound to selectively activate specific inhibitory neurons in the brain. By targeting parvalbumin interneurons in the hippocampus, researchers aim to reduce hyperexcitability and suppress seizures in Dravet syndrome. The study assesses feasibility, precision, and effectiveness in preclinical models, while also examining safety and durability of the response. The long-term goal is to develop a targeted, non-pharmacological intervention for seizure control. Coriell Institute for Medical Research 403 Haddon Ave Camden NJ 08103 210672684 501(c)(3) 9369 0 FMV Creating a biobank of patient-derived induced pluripotent stem cells. This project aims to establish a biobank of five unique lines of commercially-available induced pluripotent stem cells (iPSCs) from patient blood samples. The cellular reprogramming will be conducted by the Coriell Institute for Medical Research and samples will be housed and distributed through an additional partnership with the Orphan Disease Center at The University of Pennsylvania. Cell lines will be available to researchers in academic and for-profit research settings at a low cost, set to cover the long-term maintenance of the biobank effort. 9 0 Patient Assistance Grants. DSF supports families living with Dravet syndrome and related epilepsies through several targeted grant programs. Our Patient Assistance Grants help cover the cost of essential medical equipment, therapeutic devices, educational supports, and specialized dietary needs not funded by insurance or other programs, and are available to DSF Family Network members worldwide. Additionally, in the U.S., Disaster Relief and Recovery Grants provide $500 Visa or Amazon e-cards to families impacted by significant natural disasters to assist with urgent needs such as housing and food. Bereavement Grants offer $1,000 in flexible support to families who have lost a child, while Caregiver Connect Grants provide up to $500 to support small, regional gatherings that foster connection and peer support. 28 2373 22613 FMV Items that are currently covered under this program include: durable medical goods (such as wheelchairs, orthotics, cooling vests, etc.), therapy equipment, communication devices such as iPads, and costs associated with implementation of the ketogenic diet. By awarding these grants, DSF is making no recommendation to the appropriateness or safety of a particular piece of equipment or therapy in treating Dravet syndrome and associated epilepsies and conditions. DSF and its Board of Directors are not responsible for the safety and use of awarded equipment or therapies. Applicants are strongly urged to consult with their medical professionals and therapists regarding equipment and therapies that would be most beneficial for the situation. Caregiver Connect Grants. Caregiver Connect Grants are available from $100-$400 and can partially or fully fund a local Dravet family gathering or an ongoing Dravet support group in your area. The goal of the grants is to allow our community members to connect and receive support from one another. At this time, Caregiver Connect grants are only available for events within the United States that are members of the DSF Family Network. Funds are not available for parties for an individual child or family, awareness events, or for the benefit of individuals outside of the Dravet community. 2 800 0 FMV Schedule I, Part I, Line 2 DSF provides funds for research. The organizations receiving this assistance are required to provide written progress reports on their research into finding a cure for Dravet syndrome and related epilepsies. The Chief Scientific Officer of DSF reviews the written progress reports and discusses the research projects and progress with the awarded organization. DSF is committed to supporting families in meaningful and practical ways through a range of patient community-focused grant programs. These include: Patient Assistance Grants, which help cover the cost of essential medical and therapeutic equipment. Disaster Relief Grants, designed to provide immediate assistance to families impacted by natural disasters during times of unexpected hardship. Caregiver Connect Grants, which fund opportunities for families to come together regionally, fostering connection, shared experiences, and peer support. Bereavement Grants, offering compassionate support to families who have experienced the loss of a child. X X X X X 0 0 0 0 0 0 0 0 0 Mary Anne Meskis Chief Executive Officer 178156 0 0 0 1200 0 7165 0 0 0 186521 0 0 0 Veronica Hood PhD Chief Scientific Officer 173206 0 0 0 1200 0 6967 0 0 0 181373 0 0 0 Schedule J, Part II Compensation reported in Part VII and Schedule J reflects calendar-year Form W-2 reportable compensation. The organization accrued a bonus of $4,458 to Mary Anne Meskis and $4,182 to Veronica Hood for 2025 that was paid in 2026 and will be reported on the employee's 2026 Form W-2. Accordingly, the bonus is included in 2025 compensation expense in Part IX but not in Part VII or Schedule J for 2025. Substantial Contributor Board Trustee of Organization 150000 Contribution 0 Substantial Contributor Board Trustee of Organization 558679 Contribution 0 Schedule L, Part IV Two board members also serve on two other 501(c)(3) organizations dedicated to advancing research for Dravet syndrome. Rather than reviewing grant applications through their organizations, they prefer to support grants that our Scientific and Medical Advisory Boards have vetted and approved each year, ensuring that these projects receive the necessary resources to make a meaningful impact in the field. Form 990, Part VI, Section A, Line 4 The bylaws were amended on 09/24/2025 to update Article II, Section 2.2 to change the maximum number of voting members of the governing body from 9 to 15. Form 990, Part VI, Section B, Line 11b A copy of Form 990 and all related schedules is provided to the executive committee of the board of directors for review prior to filing with the Internal Revenue Service. Form 990, Part VI, Section B, Line 12c A conflict of interest disclosures statement is distributed and signed by each board member annually. Conflicts are dealt with on a case-by-case basis. Form 990, Part VI, Section B, Line 15 In 2025, the DSF Board of Directors established a Compensation Committee whose purpose is to ensure the Foundation's Board of Directors determines the adequacy and reasonableness of the total compensation paid to the Chief Executive Officer and compensation ranges for other senior leadership team members. The committee is responsible for 1.Conducting an annual review of the CEO's performance and total compensation in relation to the marketplace; soliciting board input regarding the CEO's performance against annual performance goals; decide on any changes in the CEO's total compensation; decided on any changes in the CEO's employment agreement, severance, and/or retention agreement, if any are in effect. 2. With respect to Senior Leadership (including the CEO), a compensation market analysis by a neutral third party consultant will be conducted every two years to gather and review in advance appropriate market comparability data on the amount and form of compensation paid for comparable executive positions by other comparable employers, including those organizations with which the Foundation may be competing for executive talent, and to assure that the comparability data gathered and reviewed meets the standard for "Appropriate Data as to Comparability" to qualify for the rebuttable presumption of reasonableness under Internal Revenue Code Section 4958. 3. Before the Board of Directors next meeting or within sixty (60) days after making its determination of reasonableness with respect to the total compensation of all team members (including the CEO) will document in a written report: (A) The terms that were approved and the date approved; (B) The members of the Compensation Committee present during the discussion and those who voted in favor and those who dissented or abstained; (C) The comparability data obtained and relied upon by the Compensation Committee and how the data was obtained; and (D) Any actions taken with respect to the determination by anyone who is otherwise a member of the committee but who had a conflict of interest. The report must be approved by the Compensation Committee as reasonably accurate and complete within a reasonable time thereafter and reported to the Board of Directors. The process described here was last completed in 2025. Form 990, Part VI, Section C, Line 19 DSF makes its governing documents and conflict of interest policy available to the public upon written request from the president. Financial statements are available for public view on the organization's website. Form 990, Part XI, Line 9 The organization recorded adjustments of $50,803 for the prior year and $42,582 for the current year to reflect changes in the net present value of long-term grants payable. These adjustments represent the periodic remeasurement of the liability, capturing the effects of the passage of time and any updates to the discount rate, in accordance with generally accepted accounting principles (GAAP).